Insulin aspart
- Generic Name
- Insulin aspart
- Brand Names
- Fiasp, Novolog, Novolog Mix, Novomix, Novorapid, Novorapid Penfill, Ryzodeg, Truvelog Mix 30, Kirsty (previously Kixelle), NovoRapid, Insulin aspart Sanofi, NovoMix
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 116094-23-6
- Unique Ingredient Identifier
- D933668QVX
- Background
Insulin aspart is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin ...
- Indication
Insulin aspart is indicated to improve glycemic control in adults and children with diabetes mellitus.
- Associated Conditions
- Diabetes Mellitus, Diabetic Ketoacidosis, Gestational Diabetes Mellitus (GDM), Hyperglycemia during critical illness
- Associated Therapies
- -
The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study
- Conditions
- Interventions
- First Posted Date
- 2013-10-22
- Last Posted Date
- 2019-10-22
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 157
- Registration Number
- NCT01966978
- Locations
- 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
Insulin by Jet-injection for Hyperglycemia in Diabetes
- First Posted Date
- 2013-09-20
- Last Posted Date
- 2014-11-26
- Lead Sponsor
- University Medical Center Nijmegen
- Target Recruit Count
- 20
- Registration Number
- NCT01947556
- Locations
- 🇳🇱
Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
A Trial Investigating the Pharmacokinetic Properties of FIAsp in Japanese Subjects With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2013-09-04
- Last Posted Date
- 2018-12-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 50
- Registration Number
- NCT01934712
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Fukuoka, Japan
A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Subjects With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2013-08-16
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 36
- Registration Number
- NCT01924637
- Locations
- 🇦🇹
Novo Nordisk Investigational Site, Graz, Austria
Comparison of IDegAsp (Inclusive Three Explorative Formulations) With Insulin Degludec and Insulin Aspart Separately Injected in Subjects With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2013-06-04
- Last Posted Date
- 2015-10-22
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 55
- Registration Number
- NCT01868568
Comparison of Explorative Formulation of Insulin Degludec and Insulin Aspart Co-formulation Versus Explorative Formulation of Insulin Degludec and Insulin Aspart Separately Compared With Biphasic Insulin Aspart 30 in Male Subjects With Diabetes
- First Posted Date
- 2013-05-30
- Last Posted Date
- 2015-10-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 59
- Registration Number
- NCT01865305
CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)
- First Posted Date
- 2013-05-08
- Last Posted Date
- 2018-11-07
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 456
- Registration Number
- NCT01848990
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time, Madison, Wisconsin, United States
A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2013-04-19
- Last Posted Date
- 2019-06-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 362
- Registration Number
- NCT01835431
- Locations
- 🇪🇸
Novo Nordisk Investigational Site, Madrid, Spain
Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2013-04-15
- Last Posted Date
- 2019-06-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1290
- Registration Number
- NCT01831765
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Sheffield, United Kingdom
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2013-03-27
- Last Posted Date
- 2019-01-30
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 881
- Registration Number
- NCT01819129
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Wrexham, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.